new drug application

new drug application
Name	New drug application
Agency	Food and Drug Administration
Jurisdiction	United States
Related	Biologics License Application, Investigational New Drug
Date first	1938

new drug application

A new drug application is the formal submission to a national regulatory authority seeking authorization to market a novel pharmaceutical product after clinical development. It summarizes preclinical data, clinical trial results, manufacturing details, and proposed labeling to demonstrate safety, efficacy, and quality for a specified indication. The NDA process connects research institutions, biotechnology firms, pharmaceutical corporations, and regulatory science across jurisdictions and influences public health, healthcare delivery, and intellectual property landscapes.

Overview

An NDA is submitted to a regulatory authority such as the Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Health Canada, Therapeutic Goods Administration, or Pharmaceuticals and Medical Devices Agency following completion of Investigational New Drug studies and pivotal clinical trials. Originators include multinational companies like Pfizer, Roche, Novartis, GlaxoSmithKline, and AstraZeneca, as well as biotechnology firms such as Amgen, Genentech, Biogen, Regeneron, and academic spinouts from institutions like Harvard University, Massachusetts Institute of Technology, Stanford University, University of Oxford, and University of Cambridge. NDAs interfacing with patent regimes often cite precedents from United States v. GlaxoSmithKline and regulatory cases adjudicated in courts such as the United States Court of Appeals for the Federal Circuit.

Regulatory Pathway and Requirements

Regulatory pathways for an NDA are shaped by statutes and guidance originating from acts and directives such as the Federal Food, Drug, and Cosmetic Act, European Directive 2001/83/EC, and international frameworks by World Health Organization and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Sponsors must meet standards exemplified by landmark approvals of drugs like penicillin, insulin, thalidomide, imatinib, and sotrastaurin (as case studies) and comply with manufacturing norms akin to Good Manufacturing Practice regimes adopted in guidelines from European Commission and national agencies including Ministry of Health, Labour and Welfare (Japan). Regulatory interactions frequently involve advisory committees modelled after panels such as the Advisory Committee on Immunization Practices and consultative processes referenced by regulators in decisions like the FDA Advisory Committee Meeting on Avastin.

Application Components

Typical NDA modules reflect the organization encouraged by the International Council for Harmonisation Common Technical Document and include: nonclinical pharmacology and toxicology data generated in laboratories such as Cold Spring Harbor Laboratory or under contracts with Charles River Laboratories; clinical trial reports from multicenter studies conducted at centers like Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and international sites in Geneva, Paris, Berlin, Tokyo, and Beijing; chemistry, manufacturing and controls (CMC) dossiers from facilities owned by corporations like Bristol-Myers Squibb and Eli Lilly and Company; and proposed labeling modeled on templates used by World Health Organization treatment guidelines. Attachments may include patents referencing United States Patent and Trademark Office filings and correspondence with payers such as Centers for Medicare & Medicaid Services and private insurers influenced by assessments from agencies like the National Institute for Health and Care Excellence.

Review and Approval Process

Regulatory review can be routine, priority, accelerated, or conditional, following paradigms established in approvals for products such as sovaldi, Keytruda, Harvoni, Spinraza, and Opdivo. Timelines vary: the Food and Drug Administration has statutory review goals such as the Prescription Drug User Fee Act timelines used in reviews for drugs like Xarelto, while the European Medicines Agency applies centralized procedures in approvals for medicines including Humira and Eylea. Review involves interdisciplinary assessment by divisions echoing expertise from institutions like National Institutes of Health, advisory input from panels analogous to Advisory Committee on Immunization Practices, and legal considerations informed by rulings involving United States Court of Appeals for the Federal Circuit and international trade disputes heard at bodies such as the World Trade Organization.

Post-Approval Obligations and Pharmacovigilance

Following approval, sponsors must fulfill pharmacovigilance commitments including postmarketing surveillance, risk evaluation and mitigation strategies comparable to those required after approvals of thrombolytics, vaccines like Gardasil, and biologics such as Humira. Reporting systems involve national pharmacovigilance centers coordinated with the World Health Organization Uppsala Monitoring Centre and databases used by regulators such as the FDA Adverse Event Reporting System and the European Medicines Agency’s EudraVigilance. Post-approval studies may be mandated as condition of marketing authorization, similar to postmarketing requirements for tamoxifen and rosiglitazone, and can affect labeling updates influenced by safety signals adjudicated through panels like the Vaccine Adverse Event Reporting System reviewers.

International Harmonization and Comparisons

Harmonization efforts by entities such as the International Council for Harmonisation, World Health Organization, Organisation for Economic Co-operation and Development, and trade agreements like the Trans-Pacific Partnership influence convergence of NDA-like submissions across jurisdictions. Comparative regulatory strategies illustrate contrasts between approvals by Food and Drug Administration and European Medicines Agency in cases like oncology drug approvals for trastuzumab and bevacizumab, and demonstrate how national policies in China, India, Brazil, and South Africa adapt ICH guidance to domestic frameworks. Cross-border reviews and reliance mechanisms are increasingly employed in cooperative initiatives between agencies such as the Medicines and Healthcare products Regulatory Agency and the Therapeutic Goods Administration to streamline access to innovative therapies.

Category:Pharmaceutical regulation